Table 1.

Base case input parameters for an analysis of ART monitoring in Mozambique.

Parameter	Base Case Value
Cohort characteristics [13]
Mean age, years (SD)	30 (10)
Median CD4,/μL (IQR)	166 (78–226)
Female, %	69
ART efficacy
Initial suppression, % [14]	79
Re-suppression after adherence intervention, % [38]	54
Annual costs (2014 US$) [16]
Clinical care
CD4 >200/μL	36
CD4 ≤200/μL	53
ART regimen costs
1st-line (tenofovir/lamivudine/efavirenz)	148
2nd-line (zidovudine/lamivudine/ritonavir/lopinavir)	389
Co-trimoxazole prophylaxis	28
ART monitoring strategies
Criteria for observed ART failure [8]
All strategies	WHO stage III or IV opportunistic infections*
Strategy-specific	LAB-CD4	POC-CD4	VL
	50% decrease in CD4 CD4 < pre-ART nadir CD4 CD4 <100/μL		VL >3,000 copies/mL
Characteristics of diagnostic tests**
Bias, %	0	− 4.1%	0
Random error, %	15.8%	19.1%	0
Test costs (2014 US$) [17, 18]	11	13	20
Time delay to clinical decision-making, months†
Adherence intervention	2	0	2
Switch to 2nd-line ART	14	11	14

SD, standard deviation; IQR, interquartile range; ART, antiretroviral therapy; WHO, World Health Organization; LAB-CD4, laboratory CD4 ART monitoring strategy; POC-CD4, point-of-care CD4 ART monitoring strategy; VL, HIV RNA ART monitoring strategy.

^*When opportunistic infections occur in patients monitored with POC-CD4₁₂, LAB-CD4₆, or POC-CD4₆, ART failure is confirmed with a CD4 test; when opportunistic infections occur in patients monitored with VL₁₂, ART failure is confirmed with an HIV RNA test.

^**Adapted from Scott et al [15]; details in Appendix; Table SDC2.

^†Adapted from Keiser et al [20].